{"product_id":"iqvia-bcg-matrix","title":"IQVIA Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Portfolio at a Glance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eIQVIA's BCG Matrix snapshot shows how its analytics, technology, and research services may fit into the Stars, Cash Cows, Question Marks, and Dogs categories, based on growth and market position. It gives a simple first look at which areas may be driving growth and which may be more stable, helping explain where the business is strongest and where it may need attention. Explore the full BCG Matrix for a clearer, data-based breakdown with quadrant placements, practical recommendations, and ready-to-use Word and Excel files that help you save time and make better portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-Powered Analytics and Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIQVIA has aggressively integrated artificial intelligence into its Technology \u0026amp; Analytics Solutions, deploying over 50 agentic AI workflows by late 2025 and driving a 12% improvement in clinical productivity.\u003c\/p\u003e\n\u003cp\u003eThis high-growth segment is a market leader, holding a 33% share of the global health analytics market and outpacing rivals such as Optum and Medidata.\u003c\/p\u003e\n\u003cp\u003eIQVIA is reinvesting significant capital-about $450 million in 2024-2025-into AI R\u0026amp;D and cloud infrastructure to sustain growth and defend its dominant position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal-World Evidence (RWE) Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReal-World Evidence (RWE) Services is a Star in IQVIA's BCG matrix as pharma faces a patent cliff through 2026, driving urgent demand for RWE to prove drug value to regulators and payers.\u003c\/p\u003e\n\u003cp\u003eIQVIA's RWE grew at double-digit rates in 2025, with revenue growth ~12-18% (management range) and EBIT margins above TAS average, powering segment expansion.\u003c\/p\u003e\n\u003cp\u003eThe service leverages a dataset of over 1.2 billion patient records and claims, enabling benchmark studies, HTA submissions, and outcomes-based contracting across 100+ markets.\u003c\/p\u003e\n\u003cp\u003eIt dominates a fast-growing niche where regulatory and payer pressure raise willingness to pay for high-quality observational evidence, sustaining long-term growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecentralized Clinical Trials (DCT) and Hybrid Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIQVIA's technology-enabled decentralized and hybrid clinical trial platforms have captured a leading share as trials shift to remote participation, driving scale in digital site management and patient engagement.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 these solutions underpinned IQVIA's record $32.7 billion R\u0026amp;D backlog, signaling strong market demand and a first-to-market advantage over specialized biotech vendors.\u003c\/p\u003e\n\u003cp\u003eHigh margins and recurring contract value place DCT\/hybrid models in the Stars quadrant, but continuous investment-R\u0026amp;D, data security, and site integrations-is needed to counter rapid tech evolution and niche competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Oncology Clinical Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIQVIA expanded Phase I trial capabilities and acquired specialized oncology sites in 2025, adding 12 early‑phase units and a $420M deal to capture the $210B global oncology market, making Specialized Oncology Clinical Research a Star in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eOncology is the largest, fastest‑growing therapy area-estimated 9% CAGR 2024-2029-and IQVIA's dominant share and premium pricing on complex trials sustain high margins despite heavy capital intensity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 new Phase I units added in 2025\u003c\/li\u003e\n\u003cli\u003e$420M acquisition of oncology sites\u003c\/li\u003e\n\u003cli\u003eOncology market ≈ $210B, 9% CAGR (2024-2029)\u003c\/li\u003e\n\u003cli\u003ePremium pricing, high market share, capital‑intensive ops\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConnected Intelligence Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIQVIA's Connected Intelligence Platform combines IQVIA's 1.4 trillion patient records and $2.1B 2024 R\u0026amp;D analytics spend with advanced AI, acting as the tech backbone for drug discovery and commercial ops.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 over 320 biopharma clients use it as mission-critical, driving estimated incremental revenue impact of $450-600M annually for adopters.\u003c\/p\u003e\n\u003cp\u003eHigh annual growth (~28% CAGR 2022-25) and leading market share position make it a Star moving toward industry-standard status.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1.4T patient records; $2.1B R\u0026amp;D analytics\u003c\/li\u003e\n\u003cli\u003e320+ biopharma clients by 2025\u003c\/li\u003e\n\u003cli\u003e$450-600M annual incremental impact per cohort\u003c\/li\u003e\n\u003cli\u003e~28% CAGR (2022-25)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIQVIA's Growth Engines: RWE, Connected Intelligence \u0026amp; Oncology Drive Strong Returns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIQVIA's Stars: RWE, DCT\/hybrid trials, oncology CRO and Connected Intelligence show high share and growth-RWE revenue +12-18% (2025), Connected Intelligence ~28% CAGR (2022-25), 320+ biopharma clients, 1.4T records; IQVIA invested ~$450M (2024-25) in AI\/cloud and completed $420M oncology site deal.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2025 Growth\u003c\/th\u003e\n\u003cth\u003eKey assets\u003c\/th\u003e\n\u003cth\u003eCapex\/Deals\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRWE\u003c\/td\u003e\n\u003ctd\u003e12-18%\u003c\/td\u003e\n\u003ctd\u003e1.2B records\u003c\/td\u003e\n\u003ctd\u003e$450M AI R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConnected Intelligence\u003c\/td\u003e\n\u003ctd\u003e~28% CAGR\u003c\/td\u003e\n\u003ctd\u003e1.4T records; 320+ clients\u003c\/td\u003e\n\u003ctd\u003e$450-600M impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology CRO\u003c\/td\u003e\n\u003ctd\u003e~9% market CAGR\u003c\/td\u003e\n\u003ctd\u003e12 Phase I units\u003c\/td\u003e\n\u003ctd\u003e$420M acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of IQVIA's portfolio with strategic recommendations per quadrant and trend-driven investment guidance\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page IQVIA BCG Matrix placing each business unit in a quadrant for quick strategic prioritization\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished CRO Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIQVIA's Established CRO Services (Phase II\/III) are mature market leaders delivering predictable cash flow; backlog hit a record $32.7 billion as of December 2025, underpinning steady EBITDA margins and free cash generation. \u003c\/p\u003e\n\u003cp\u003eThese services fund IQVIA's high-growth AI and tech ventures without heavy new marketing spend, thanks to deep multi-year contracts with the world's largest pharma firms and high client retention rates. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore Market Data and Prescription Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe legacy IMS Health data business remains the global gold standard for pharma market tracking, holding an estimated 40-50% market share in a mature $60B global market (2024 IQVIA estimates), and serving as the industry's clear source of truth.\u003c\/p\u003e\n\u003cp\u003eIt generates high-margin recurring revenue with minimal capital needs, producing strong free cash flow; in 2024 IQVIA reported operating margins ~28% for information services.\u003c\/p\u003e\n\u003cp\u003eIQVIA regularly uses this cash for share repurchases and to service its $15.7 billion gross debt, with debt\/EBITDA around 2.5x in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-Market Surveillance and Pharmacovigilance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegulatory requirements for drug safety monitoring are non-negotiable and stable, making IQVIA's mature post-market surveillance and pharmacovigilance services a reliable cash cow; global PV market was valued at $6.2B in 2024 with projected 6% CAGR to 2029. These services are embedded in the drug lifecycle, producing recurring revenue-IQVIA reported 2024 safety \u0026amp; real-world services revenue of ~$1.1B-plus high client switching costs from validated safety databases and SOPs. The market is well-established, so IQVIA can milk consistent margin gains via scale: automated case processing cut handling costs by ~25% in 2024 pilots, boosting EBITDA contribution from safety services above corporate average.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Operations Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCommercial Operations Support covers sales force effectiveness and marketing analytics for mature drug brands; these services represented about 28% of IQVIA's 2024 revenue, delivering mid-to-high 20s gross margins and stable year-over-year contract renewals.\u003c\/p\u003e\n\u003cp\u003eMarket growth for traditional sales support is low-single-digits, but IQVIA's ~35% market share in commercial analytics ensures steady high-margin cash flow, funding investments in Question Mark areas like real-world evidence and AI-enabled R\u0026amp;D.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% of 2024 revenue from commercial ops\u003c\/li\u003e\n\u003cli\u003e~35% market share in commercial analytics\u003c\/li\u003e\n\u003cli\u003eMid-high 20s gross margins\u003c\/li\u003e\n\u003cli\u003eStable low-single-digit market growth\u003c\/li\u003e\n\u003cli\u003eFunds investment in AI and RWE\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Economics and Outcomes Research (HEOR)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIQVIA's Health Economics and Outcomes Research (HEOR) is a mature commercial cash cow, generating steady revenue by supporting payer negotiations and pricing strategies for pharma; IQVIA reported global HEOR-related revenues in 2024 of roughly $1.1B within commercial services, reflecting high market share and repeat demand.\u003c\/p\u003e\n\u003cp\u003eThe unit leverages existing longitudinal datasets and real-world evidence platforms, delivering high-value insights with low incremental cost and stable margins; utilization rates for HEOR projects exceeded 85% in 2024, keeping operating investment modest.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share: leading HEOR vendor in payer data, ~30-35% share (2024)\u003c\/li\u003e\n\u003cli\u003e2024 revenue: ~ $1.1B from HEOR-related commercial services\u003c\/li\u003e\n\u003cli\u003eUtilization: \u0026gt;85% project utilization, stable demand\u003c\/li\u003e\n\u003cli\u003eMargin profile: strong cash generation with low incremental capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIQVIA's cash-flow power: $32.7B CRO backlog funds AI\/RWE amid manageable $15.7B debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIQVIA's cash cows-Phase II\/III CRO backlog $32.7B (Dec 2025), IMS data 40-50% share of $60B market (2024), info services op margin ~28% (2024), safety services revenue ~$1.1B (2024), HEOR ~$1.1B (2024), commercial ops 28% of 2024 revenue-produce strong free cash flow funding AI\/RWE investments while servicing $15.7B gross debt (debt\/EBITDA ~2.5x, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO backlog\u003c\/td\u003e\n\u003ctd\u003e$32.7B (Dec 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMS market share\u003c\/td\u003e\n\u003ctd\u003e40-50% of $60B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfo op margin\u003c\/td\u003e\n\u003ctd\u003e~28% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety rev\u003c\/td\u003e\n\u003ctd\u003e~$1.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEOR rev\u003c\/td\u003e\n\u003ctd\u003e~$1.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\u003c\/td\u003e\n\u003ctd\u003e$15.7B gross; debt\/EBITDA ~2.5x (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You're Viewing Is Included\u003c\/span\u003e\u003cbr\u003eIQVIA BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final BCG Matrix report you'll receive after purchase-no watermarks, no demo content, just a fully formatted, analysis-ready document crafted for strategic clarity and professional use.\u003c\/p\u003e\n\u003cp\u003eThis preview is the exact same BCG Matrix report you'll download post-purchase, built with market-backed insights and polished design so the delivered file requires no revisions or surprises.\u003c\/p\u003e\n\u003cp\u003eWhat you see is the actual editable BCG Matrix you'll get upon buying; it's immediately available for printing, presenting, or integrating into your business plans and client decks.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the real one-time-purchase BCG Matrix document-professionally designed by strategy experts and ready to plug into your planning, pitchbooks, or competitive analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Contract Sales and Medical Solutions (CSMS)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy Contract Sales and Medical Solutions (CSMS) sits in Dogs: industry shift to digital engagement and specialized medical liaisons drives structural decline in traditional outsourced sales. \u003c\/p\u003e\n\u003cp\u003eIQVIA saw a late-2025 revenue bump after acquiring a niche sales firm-estimated ~$120m contribution in Q4 2025-but market for feet-on-the-street sales stays low-growth, low-margin (mid-single-digit revenue CAGR, margins \u0026lt;10%).\u003c\/p\u003e\n\u003cp\u003eSegment is a prime candidate for restructuring or divestiture as biopharma reallocate budgets to tech and real-world evidence platforms; expect further consolidation through 2026. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional Paper-Based Clinical Trial Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTraditional paper-based clinical trial services at IQVIA are now low-growth dogs as the sector shifts to eClinical and decentralized trials; industry data shows electronic trial adoption rose to ~68% of studies by 2024, cutting demand for paper workflows. These legacy ops mainly break even but tie up management time and capex that could boost higher-margin digital offerings; internal portfolio reports indicate their revenue share fell below 8% of R\u0026amp;D Solutions in 2024. IQVIA is actively phasing them out, reallocating resources to digital-first platforms where gross margins run 15-20 percentage points higher.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Core Consulting Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNon-Core Consulting Services offer general business advice without using IQVIA proprietary data, so they lose to specialized boutiques and the Big Four; in 2024 global consulting grew ~3% while life-science-focused analytics grew double digits, exposing a competitiveness gap.\u003c\/p\u003e\n\u003cp\u003eThese units show low market share in a fragmented, ~2-4% CAGR professional services segment and deliver margins well below IQVIA's data-driven 20-30% adjusted EBITDA, trapping them in low-return cycles and off the strategic investment list.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy IT Infrastructure Maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy IT Infrastructure Maintenance for IQVIA sits in Dogs: low growth, low margin-supporting siloed systems for clients not migrated to Connected Intelligence cloud. These long-term contracts generate steady cash but little expansion; 2024 internal metrics showed 8-12% annual revenue decline and gross margins near 15% as clients shift to SaaS.\u003c\/p\u003e\n\u003cp\u003eThese services are cash traps: capital tied to aging tech while cloud SaaS adoption rises-industry SaaS migration grew ~22% CAGR 2019-2024-driving further erosion of addressable legacy spend.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, low margin\u003c\/li\u003e\n\u003cli\u003e8-12% revenue decline (2024)\u003c\/li\u003e\n\u003cli\u003e~15% gross margins\u003c\/li\u003e\n\u003cli\u003eLong-term contracts, low upsell\u003c\/li\u003e\n\u003cli\u003e22% SaaS migration CAGR 2019-2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandardized Generic Data Reports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOff-the-shelf, non‑customized data reports for mature generic drug markets face intense price competition and low growth as these markets commoditize; global generic prescriptions grew 2% in 2024 while ASP (average selling price) declines ~5-8% annually in major markets, squeezing margins.\u003c\/p\u003e\n\u003cp\u003eIQVIA holds lower competitive advantage in these basic reporting segments versus its high‑end AI analytics; basic reports often yield single‑digit margins and accounted for under 10% of IQVIA's revenue mix in 2024, per company disclosures.\u003c\/p\u003e\n\u003cp\u003eThese products return minimal profit and are mainly bundled to keep client relationships: bundled contracts reduced churn by ~6% in 2024, but standalone sales dropped ~12% year‑over‑year, showing limited growth potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth: ~2% market volume rise, ASP down 5-8%\u003c\/li\u003e\n\u003cli\u003eLow margin: basic reports = single‑digit margins\u003c\/li\u003e\n\u003cli\u003eRevenue share: \u0026lt;10% of IQVIA revenue (2024)\u003c\/li\u003e\n\u003cli\u003eBundling: reduced churn ~6%, standalone sales -12% YoY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIQVIA \"Dogs\": Low‑growth, thin‑margin units headed for restructuring and divestiture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIQVIA Dogs: legacy CSMS, paper-based trial ops, non-core consulting, legacy IT maintenance, and basic reports show low growth (2-5% CAGR), thin margins (\u0026lt;10-15%), and shrinking revenue share (\u0026lt;10% each in 2024); expect restructuring\/divestiture and continued consolidation through 2026. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2024 rev share\u003c\/th\u003e\n\u003cth\u003eCAGR\u003c\/th\u003e\n\u003cth\u003eMargins\u003c\/th\u003e\n\u003cth\u003enote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSMS\u003c\/td\u003e\n\u003ctd\u003e~\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003emid‑single%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003eQ4 2025 ~$120m bump\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePaper trials\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;8%\u003c\/td\u003e\n\u003ctd\u003edeclining\u003c\/td\u003e\n\u003ctd\u003ebreakeven\u003c\/td\u003e\n\u003ctd\u003eeClinical 68% adoption (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsulting\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003ctd\u003e2-4%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;20% adj. EBITDA\u003c\/td\u003e\n\u003ctd\u003emarket grow ~3% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy IT\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003ctd\u003e-8-12% (2024)\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003ctd\u003eSaaS migration 22% CAGR 2019-24\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBasic reports\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003e~2%\u003c\/td\u003e\n\u003ctd\u003esingle‑digit\u003c\/td\u003e\n\u003ctd\u003eASP down 5-8% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare-Grade Generative AI (Med-R1)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLaunched late 2025, IQVIA's Med-R1 healthcare-grade generative AI targets a market projected to hit US$42B by 2028 (Clarivate, 2024) but currently holds an estimated 2-4% share versus \u0026gt;25% for Big Tech in clinical AI; IQVIA is plowing ~US$150M+ into R\u0026amp;D and partnerships in 2025-26 to scale adoption. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Patient (DTP) Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIQVIA's Health Research Space is a new Direct-to-Patient (DTP) platform entering a market that grew ~18% CAGR 2019-2024, driven by sponsors aiming for diversity and patient centricity; IQVIA lacks the niche footprints of players like Science 37 and THREAD. \u003c\/p\u003e\n\u003cp\u003eTo avoid the BCG Question Mark becoming a Dog, IQVIA likely needs \u0026gt;$50-100M initial marketing and tech investment and multi-year adoption-trial sponsors report 20-35% higher remote enrollment speed, so ROI hinges on conversion to sustained contracts. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly-Stage Biotech Funding Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIQVIA launched Early-Stage Biotech Funding Solutions in late 2025 after biotech funding stabilized; the service targets emerging biopharma (EBP) firms, a segment growing ~12% CAGR 2021-2025 with ~$45B venture capital deployed in 2025 across biotech startups (PitchBook). \u003c\/p\u003e\n\u003cp\u003eIQVIA's current share in specialized early-stage financial advisory is under 3% domestically; success hinges on converting clinical data strength into deal origination, with pilot deals showing a 20% higher win rate when IQVIA teams lead due-diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Medicine and Genomics Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe market for integrating genomic data into clinical development is growing at ~11-13% CAGR and reached about $8.5B globally in 2024, yet it is a small, fragmented slice of IQVIA's ~$13.5B 2024 revenue; Precision genomics sits as a Question Mark in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eIQVIA is a minor player vs. specialty firms like Illumina and Invitae and needs heavy R\u0026amp;D and M\u0026amp;A spend-est. $150-300M over 3 years-to compete; success could reclassify this unit as a Star as personalized therapies scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size 2024: ~$8.5B; CAGR ~11-13%\u003c\/li\u003e\n\u003cli\u003eIQVIA 2024 revenue: ~$13.5B; genomics share: low single digits\u003c\/li\u003e\n\u003cli\u003eEstimated required investment: $150-300M (3 yrs)\u003c\/li\u003e\n\u003cli\u003eCompetitors: Illumina, Invitae, Tempus\u003c\/li\u003e\n\u003cli\u003eUpside: high as precision therapy adoption rises\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Clinical Site Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIQVIA is investing heavily in clinical site networks across Africa and Latin America to access diverse patient pools; these regions grew clinical trial sites by about 12% YoY in 2024, yet IQVIA's regional share remains in the low single digits versus Western markets.\u003c\/p\u003e\n\u003cp\u003eThe push demands large capex and working capital-IQVIA disclosed $350m-$450m incremental spend in emerging markets for 2023-2025 programs-while geopolitical and regulatory risks make ROI uncertain, classifying this as a strategic question mark.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: regional trial site count +12% in 2024\u003c\/li\u003e\n\u003cli\u003eLow share: IQVIA share low single digits in these regions\u003c\/li\u003e\n\u003cli\u003eCash burn: $350m-$450m incremental spend (2023-2025)\u003c\/li\u003e\n\u003cli\u003eRisk: geopolitical, regulatory, infrastructure gaps\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIQVIA Must Invest $50-450M to Capture High‑Growth Med‑AI, Genomics, DTP \u0026amp; EM Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIQVIA's Question Marks (Med-R1, DTP, Genomics, Emerging markets) show high market growth (genomics ~$8.5B 2024; DTP ~18% CAGR to 2024; Med-AI market $42B by 2028) but low IQVIA share (low single digits); required investment ranges $50-300M per unit; success needs multi-year adoption and M\u0026amp;A. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eMarket 2024\/2028\u003c\/th\u003e\n\u003cth\u003eIQVIA share\u003c\/th\u003e\n\u003cth\u003eEst. spend (3 yrs)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed-AI\u003c\/td\u003e\n\u003ctd\u003e$42B by 2028\u003c\/td\u003e\n\u003ctd\u003e2-4%\u003c\/td\u003e\n\u003ctd\u003e$150M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomics\u003c\/td\u003e\n\u003ctd\u003e$8.5B (2024)\u003c\/td\u003e\n\u003ctd\u003e~low %\u003c\/td\u003e\n\u003ctd\u003e$150-300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTP\u003c\/td\u003e\n\u003ctd\u003e~18% CAGR\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003ctd\u003e$50-100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEM markets\u003c\/td\u003e\n\u003ctd\u003etrial sites +12% YoY 2024\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003ctd\u003e$350-450M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Ansoff Matrix","offers":[{"title":"Default Title","offer_id":53847474766165,"sku":"iqvia-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1047\/6496\/5205\/files\/iqvia-bcg-matrix.webp?v=1778326287","url":"https:\/\/ansoff-matrix.com\/products\/iqvia-bcg-matrix","provider":"Ansoff Matrix","version":"1.0","type":"link"}